A Phase III Randomized Double-Blind Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
-
- STATUS
- Recruiting
Summary
The purpose of the study is to compare letermovir to valganciclovir in preventing CMV disease in patients who have received a kidney transplant and are considered to be at high-risk for CMV disease after their transplant. The main study intervention is taking letermovir (or placebo for letermovir) plus valanciclovir (or placebo for valganciclovir) for 28 weeks after kidney transplant, instead of receiving the standard of 6 months valganciclovir post-transplant.
Details
| Condition | TBD |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | 03443869 |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.